Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Dow
Baxter
Medtronic
Harvard Business School

Last Updated: October 1, 2022

KINERET Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Recent Clinical Trials for KINERET

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Monash Medical CentrePhase 1/Phase 2
Monash UniversityPhase 1/Phase 2
SobiPhase 3

See all KINERET clinical trials

Recent Litigation for KINERET

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AMGEN INC. v. APOTEX INC.2022-06-14
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
AMGEN INC. v. EMCURE PHARMACEUTICALS LTD.2018-06-28

See all KINERET litigation

PTAB Litigation
PetitionerDate
2015-06-02
2012-09-25

See all KINERET litigation

Pharmacology for KINERET
Mechanism of ActionInterleukin 1 Receptor Antagonists
Established Pharmacologic ClassInterleukin-1 Receptor Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KINERET Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KINERET Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 See Plans and Pricing 2008-12-24 Company disclosures
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 See Plans and Pricing 2020-07-29 Company disclosures
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 See Plans and Pricing 2022-02-22 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for KINERET Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for KINERET

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2002C/023 Belgium See Plans and Pricing PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001 20020311
10299011 Germany See Plans and Pricing PRODUCT NAME: KINERET(R) (WIRKSAMER BESTANDTEIL ANAKINRA); REGISTRATION NO/DATE: EU/1/02/203/001-004 20020308
SPC/GB02/026 United Kingdom See Plans and Pricing PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308
SZ 23/2002 Austria See Plans and Pricing PRODUCT NAME: ANAKINRA
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
Johnson and Johnson
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.